Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I

Yusuke Oshima1,2, Koji Sato1, Fumi Tashiro3, Jun-ichi Miyazaki3, Koji Nishida2, Yuji Hiraki1, Yasuo Tano2 and Chisa Shukunami1,*

1Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
2Department of Ophthalmology and 3Department of Nutrition and Physiological Chemistry, Osaka University Medical School, Suita 565-0871, Japan
*Author for correspondence (e-mail: shukunami@frontier.kyoto-u.ac.jp)

Accepted 20 January 2004
Journal of Cell Science 117, 2731-2744 Published by The Company of Biologists 2004
doi:10.1242/jcs.01112

Summary
Tenomodulin (TeM) is a type II transmembrane glycoprotein that contains a C-terminal domain with homology to the mature, secreted form of chondromodulin-I (ChM-I), a cartilage-derived angiogenesis inhibitor. TeM transcripts have been found in hypovascular tissues such as tendons and ligaments but the biological activity of TeM has not yet been fully explored. Using an adenovirus expression system, we utilized the forced expression and subsequent secretion of the human TeM C-terminal 116 amino acids (Ad-shTeM) in human umbilical vein endothelial cells (HUVECs) to assess the anti-angiogenic properties of TeM. The C-terminal 120 amino acids of the human ChM-I precursor (Ad-shChM-I) was similarly expressed in HUVECs as a comparison study. Transduction of both Ad-shTeM and Ad-shChM-I resulted in significant impairment of the tube-forming activity of HUVECs when cultured in Matrigel. Similarly, conditioned medium from COS7 cells, transfected with plasmid DNA encoding shTeM or shChM-I, inhibited tube formation of HUVECs when compared to medium derived from either COS7 cells transfected with control vector or from non-transfected cells.

Upon infection of HUVECs with Ad-shTeM or Ad-shChM-I, DNA synthesis stimulated by vascular endothelial growth factor (VEGF) was reduced to 40-50% of normal levels. Additionally, in a modified Boyden chamber assay, migration of HUVECs in response to VEGF was significantly affected following transduction of either Ad-shTeM or Ad-shChM-I and these transduced HUVECs were found to spread well on type I collagen or fibronectin, but not on vitronectin. Furthermore, the transduction of either Ad-shTeM or Ad-shChM-I in human melanoma cells resulted in suppression of tumor growth in association with decreased vessel density in vivo. Hence, we have demonstrated that, similarly to ChM-I, the C-terminal domain of TeM exhibits both anti-angiogenic and anti-tumor activities when expressed in a secreted form.

Key words: Angiogenesis inhibitor, Tenomodulin, Chondromodulin-I, Tendon

Introduction
The balance between stimulators and inhibitors of angiogenesis plays a dynamic role in the regulation of tissue vascularity during development and growth. Under some pathological conditions, however, an imbalance between these factors disturbs the vascular quiescence that needs to be maintained in adult tissues. It has been well documented that vascular endothelial growth factor (VEGF) and angiopoietin, among others, play central roles in the induction of angiogenesis (Carmeliet et al., 1996; Suri et al., 1996). Identification of the tumor-generated angiogenesis inhibitors, angiostatin and endostatin, have also shed light on the importance of such negative regulators during the maintenance of tissue vascularity (O’Reilly et al., 1997; O’Reilly et al., 1994).

In order to identify novel physiological inhibitors of angiogenesis, we previously characterized the growth inhibitory activity of vascular endothelial cells from fetal cartilage, which is known to be typical avascular tissue (Hiraki et al., 1997). We isolated and purified the factor that promoted this growth inhibition, and subsequent amino acid sequencing identified it as chondromodulin-I (ChM-I) (Hiraki et al., 1991). Transfection of ChM-I precursor cDNAs into either COS7 cells or CHO cells resulted in secretion of mature ChM-I (120 amino acids) as a 25 kDa glycoprotein following processing at the furin cleavage site of the type II membrane ChM-1 precursor protein (Azizan et al., 2001; Hiraki et al., 1997; Hiraki et al., 1999). In situ hybridization and immunohistochemistry indicated that ChM-I is specifically localized in the avascular zone of cartilage during endochondral bone formation (Hiraki et al., 1997; Shukunami et al., 1999). We demonstrated that purified recombinant human ChM-I inhibited tumor angiogenesis and growth in vivo (Hayami et al., 1999) and also stimulated proliferation of chondrocytes and osteoblasts (Hiraki et al., 1991; Mori et al., 1997). Our recent analysis of ChM-I knockout mice revealed an osteopetrotic phenotype,
suggested that ChM-I acts as a bone remodeling factor following birth (Nakamichi et al., 2003).

Three independent groups have previously reported the identification of a novel gene encoding tenomodulin (TeM), which has homology to ChM-I (Brandau et al., 2001; Shukunami et al., 2001; Yamana et al., 2001). TeM is a putative type II transmembrane protein (317 amino acid residues) that has a domain at the C terminus (Phe255-Val317) with homology to the cysteine-rich domain of the ChM-I precursor (Phe272-Val334). Within this 63 amino acid region, 42 amino acids are identical between TeM and ChM-I. All eight cysteine residues in the mature ChM-I protein are present in this domain and form four intramolecular disulfide bonds (Hiraki et al., 1991; Neame et al., 1990). These bonds are critical for the bioactivity of ChM-I, which is abrogated by their reduction (Hiraki et al., 1997; Hiraki et al., 1999).

Although the TeM and ChM-I precursor proteins have only limited sequence identity outside their cysteine-rich domains, they show remarkable similarity in their structural motifs in these outside regions, including the presence of a hydrophobic transmembrane domain at the N-terminal side and a BRICHOS domain at their center (Sanchez-Pulido et al., 2002). The TeM protein, however, lacks a complete furin cleavage site (Fig. 1). In the present study, we first confirmed that TeM was expressed as a type II transmembrane protein: transfection of TeM cDNA in COS7 cells resulted in the expression of a 40-45 kDa cell surface protein without any appreciable intra-molecular cleavage, as assessed by western blot analysis. Cell-surface TeM was identified as a type II transmembrane protein by a cell-surface biotinylation technique and subsequent confocal immunofluorescence analysis of transfected COS7 cells expressing the entire hTeM coding region. Further western blot analysis also detected endogenous TeM protein in extracts of skeletal muscle as 40-45 kDa double immunoreactive bands.

Materials and Methods

Reagents

Anti-FLAG monoclonal antibody (M2) was purchased from Sigma-Aldrich (St Louis, MO, USA). Anti-TeM polyclonal antibodies against a polypeptide corresponding to the human/mouse TeM protein sequence between amino acids 127-136 were generated by our laboratory. VEGF was purchased from R&D (Minneapolis, MN, USA).

Cell culture

COS7 cells were obtained from the Japanese Collection Research Resources Cell Bank and were cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C under 5% CO2 in air. The 293 human embryonic kidney cell line, constitutively producing adenovirus E1 proteins, was purchased from Clonetics and maintained in DMEM containing 10% FBS at 37°C under 5% CO2 in air. Human umbilical vein endothelial cells (HUVECs) were also obtained commercially (Clonetics) and grown in EGM2 medium (EBM complete medium with supplements; Clonetics) at 37°C under 5% CO2 in air. Cells growing at between passages 4 and 8 were used in the experiments. The murine melanoma cell line (BL-6) (Nakayama et al., 1994) was kindly donated by the Department of Dermatology, Osaka University Graduate School of Medicine (Suita, Japan) and the cells were grown in DMEM/HAMF-12 containing 10% FBS.

Plasmid construction and transfection

The entire coding region of human TeM cDNA (hTeM: GenBank Accession No. AF234259) was performed by 5' and 3'-RACE (rapid amplification of cDNA ends) using Marathon Ready human fetal cDNA (Clontech, Palo Alto, CA) and the following oligonucleotide primers: forward (5'-GAG ACC ATG GCA AAG AAT CCT CC-3'), reverse (5'-CTC TTA TGA GCC CCT CCC CAG C-3'). The amplified hTeM cDNA was subcloned into the SstI site of the pCR-Script vector (Stratagene, La Jolla, CA, USA) and verified by sequencing. N-terminal and C-terminal FLAG-tagged hTeM (FLAG-hTeM and hTeM-FLAG, respectively) were then generated by PCR from the pCR-Script-hTeM construct using the following primers: forward primer 1 (5'-GGG CGA ATT TTC TAC TAC GTA CAA AAG GGA CAA GAA GAA GCC AAA TCC TCC AG-3'), reverse primer 1 (T3 primer: 5'-AAT TAA CCC TCA TTA AAG GG-3'), reverse primer 2 (5'-GCG CGC GCC GCC TCA CTT GTC ATC TTC TTT GTA GTC GAC CCT CCC CAG CAG CCG GGC GGC-3') for hTeM-FLAG. FLAG-hTeM and hTeM-FLAG amplified cDNAs were then cloned into the EcoRI site of pCAGGS, a previously described mammalian expression vector (Niwa et al., 1991), resulting in the pCAGGS-FLAG-hTeM and pCAGGS-hTeM-FLAG vectors, respectively.

To enable forced secretion of the 116-amino acid C terminus of human TeM (shTeM; Glu202-Val317) and the 120-amino acid C terminus of the human ChM-I precursor to mature ChM-I (shChM-I; Glu215-Val334), the corresponding cDNA fragments were generated by PCR using the following primers: forward primer 3 (5'-GAG GGA GAA GAT CTT CAC TTG TTG-3'), reverse primer 3 (5'-AAT TAA CCC TCA TTA AAG GG-3') for shTeM and forward primer 4 (5'-GAA GTG GTA AGA AAA ATT GTT CC-3'), reverse primer 4 (5'-GGG CGC CCG CTC ACT CCA TGC CCA AGA TAC GGG C-3') for shChM-I. The amplified cDNA fragments encoding shTeM and shChM-I were separately cloned into the EcoRI site of the pCAGGS vector which contained both the preprotrypsin secretion signal and FLAG epitope upstream of the MCS, resulting in the pCAGGS-FLAG-shTeM and pCAGGS-FLAG-shChM-I vectors, respectively.

Transfection of cloned expression vectors into COS7 cells was performed using Lipofectamine 2000 (Gibco-BRL, Gaithersburg, MD, USA) according to the manufacturer’s instructions.

Western blot analysis

Cell culture medium was collected and then eluted through a Butyl-Toyopearl column (Tosoh, Tokyo, Japan). After preincubation with blocking buffer (5% nonfat milk, 2% SDS, 5% β-mercaptoethanol, and 10% glycerol), the corresponding adherent cells were washed twice with PBS and an equivalent amount of 1× SDS sample buffer was then added. Cell lysates were harvested and cleaned by centrifugation. Muscle and liver samples, dissected from 4-week-old DDY mice, were homogenized in buffer containing 8 M urea, 50 mM Tris-HCl (pH 8.0), 1 mM diithiothreitol, and 1 mM EDTA and the resulting tissue extracts were centrifuged to remove cellular debris. Aliquots (~200 μg of total protein) of each supernatant were diluted in 2× SDS sample buffer.

Samples were electrophoresed on 12.5% SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). After preincubation with blocking buffer (5% nonfat milk, 0.1% Tween 20, and 0.1% NaN3 in PBS), the membranes were incubated with either rabbit anti-TeM polyclonal antibody against the synthetic peptide corresponding to the human/mouse TeM sequence from Thr234 to Glu336, or anti-FLAG monoclonal antibody M2 (Sigma-Aldrich, St Louis, MO, USA) followed by horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibody or HRP-conjugated anti-mouse IgG antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA), respectively. Peroxidase activity was detected...
and visualized by the enhanced chemiluminescence (ECL) plus system (Amersham Pharmacia Biotech) according to the manufacturer’s instructions.

Cell surface biotinylation and immunoprecipitation

COS7 cells transiently transfected with either the pCAGGS-FLAG-hTeM or the pCAGGS-hTeM-FLAG vector were biotinylated on the cell surface using the ECL protein biotinylation system (Amersham Pharmacia Biotech). Cells were solubilized with lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1% Triton-X100) and cell lysate proteins were immunoprecipitated with anti-FLAG monoclonal antibody M2 (Sigma-Aldrich), resolved by SDS-PAGE and immunoblotted with either streptavidin-DRP or anti-TeM polyclonal antibody. Proteins were visualized by ECL plus (Amersham Pharmacia Biotech).

Cell surface binding

COS7 cells transiently expressing the entire coding region of TeM tagged with FLAG were grown in a Lab-Tek II CC2 chamber slide (NALGE Nunc International Corp, Naperville, IL, USA) in DMEM supplemented with 10% FCS. The cells were then incubated with anti-FLAG M2 antibodies conjugated to FITC (1:100, Sigma Aldrich) for 2 hours at 4°C. Following extensive washing three times with cold DMEM to remove unbound antibody, the cells were fixed in PBS containing 4% paraformaldehyde for 10 minutes and then washed with TBS three times and mounted with Prolong Antifade (Molecular Probes). Cells transfected with empty vector were used as a negative control. Antibody labeling was visualized on a Zeiss LSM510 Laser-scanning microscope and image analysis was performed using the standard system operating software.

Adenovirus construction and production

FLAG-shChM-I, FLAG-shTeM and FLAG-hTeM cDNA fragments were subcloned into the EcoRI restriction site of pCAGGS containing an upstream preprotrypsin secretion signal and FLAG epitope (Niwa et al., 1991). These three FLAG-tagged inserts were then subcloned into the pKSCX-EGFP construct (Tashiro et al., 1999). The pKSCX-EGFP expression cassette is flanked by SswI sites and contains a strong CAG promoter, IRES, EGFP and a poly(A) signal, respectively. The expression cassette of FLAG-shTeM (4.4 kb), FLAG-shChM-I (4.4 kb) or FLAG-hTeM (5.1 kb) was excised by digestion with SswI, ligated with SswI-digested pALC3.0 containing the E1-defective adenoviral genome, and introduced into E. coli with an in vitro lambda phage packaging kit (Stratagene) according to the manufacturer’s instructions.

The preparation method for the replication-defective E1-recombinant adenoviral vector has been previously described (Tashiro et al., 1999). Briefly, to generate infectious recombinant adenoviral vectors, 1 μg of the indicated expression cosmids and 0.1 μg of pMC1-Cre for the expression of Cre recombinase were cotransfected into 293 cells using Lipofectamine 2000 (Gibco-BRL). Cytopathic effects (CPE) were visible within 10 days and the culture media from cells with CPE were harvested and centrifuged to obtain supernatant fractions containing adenoviral vectors. After addition of the supernatant to 293 cells grown in large scale cultures for several further days, 293 cells with complete CPE were harvested, lyzed by six cycles of freezing and thawing, and centrifuged at 3500 rpm for 10 minutes at 4°C. The supernatants, which contained the adenoviral vector, were titrated according to standard procedures described previously (Tashiro et al., 1999). Contamination by replication-competent virus was ascertained by infecting COS7 cells and HUVECs with viral stocks and there was no sign of viral replication in the experimental cells. All manipulations of adenoviral vectors were performed in accordance with both institutional and national biosafety regulations.

Adenoviral gene transduction of HUVECs

HUVECs in culture prior to passage 8 were seeded in 75 cm² flasks and grown with 15 ml EGM2 medium to approximately 80% confluence. The cells were then infected with the indicated adenoviral vectors at a multiplicity of infection (MOI) of 10² to 10³ plaque forming units (pfu) per cell for 6 hours, washed twice with PBS, replenished with the fresh EGM2 medium, and further cultured for subsequent experiments. The transduction efficiency of adenoviral infection was monitored by fluorescent microscopy (Carl Zeiss, Munich, Germany).

Dil-Ac-LDL uptake

To confirm both the presence and maintenance of vascular endothelial characteristics following adenoviral transduction, Ac-LDL uptake assays were performed in uninfected HUVECs (wild type) and in HUVECs infected with the indicated adenoviral vectors. Cells were incubated with 10 μg/ml Dil-Ac-LDL (Molecular Probes, Leiden, The Netherlands) in EGM2 medium for 6 hours and further incubated with 10 nM Hoechst 33342 (Sigma-Aldrich) for 2 hours. Dil-Ac-LDL uptake in living cells was analyzed using a fluorescence microscope, and merged images were generated with imaging software (Carl Zeiss).

DNA synthesis

HUVECs at early passages (4–8) were harvested with trypsin/EDTA and subjected to ECL at a density of 50,000 cells/ml. The cells were seeded into a 96-well collagen I-coated plate (100 μl per well) and grown to subconfluence. The cells were then stained in 0.5% PBS-containing contains MEM for 6 hours and stimulated with 20 ng/ml VEGF (R&D, Minneapolis, MN, USA) for another 12 hours. Cells were labeled with BrdU during the last 4 hours of this incubation. A MAP kinase inhibitor, PD98059 (New England Biolabs, Beverly, MA, USA) was used at a concentration of 50 μM. Incorporation of BrdU into DNA was determined with a bromo-2′-deoxyuridine labelling kit III according to the manufacturer’s instructions (Roche, Basel, Switzerland). Absorbencies at 405 nm were measured using a Model 450 Microplate Reader (Bio-Rad, Hercules, CA, USA).

Matrigel tube formation assay

24-multwell culture plates (Costar, Corning, NY) were coated with growth factor-reduced Matrigel (0.4 ml; Becton Dickinson Labware, Bedford, MA, USA) and incubated at 37°C for 30 minutes. HUVECs starved for 4 hours were treated with trypsin-EDTA and suspended in the culture medium for 20 minutes. The cells were seeded at a density of 50,000 cells/well on polymerized Matrigel in the presence of VEGF (20 ng/ml). After incubation at 37°C for 6 hours, photographs were taken under a phase contrast light microscope (Carl Zeiss). To quantitatively evaluate the capillary-like morphogenesis of HUVECs, total lengths of tube-like structures per field were measured using image processing and analysis software (NIH image version 1.61, available in the public domain via the National Institute of Health, Bethesda, MD). Each experiment was performed four times.

Adhesion and spreading assays

Adhesion assays were performed essentially as described elsewhere (Tang et al., 1999) with minor modifications. Briefly, both transduced and wild-type early-passage (4-8) HUVECs were cultured for 24 hours, harvested with trypsin/EDTA and suspended in the culture medium for 20 minutes. After re-suspension of cells at a density of 5x10⁵ cells/ml in αMEM containing 0.1% BSA, cells were inoculated in 96-multwell plates coated with either type I collagen, fibronectin or vitronectin (100 μl per well), and were incubated for 1 hour at 37°C. Cells were then rinsed with PBS, fixed with 4%...
paraformaldehyde in PBS for 30 minutes, rinsed again with PBS, stained with 0.2% crystal violet in 80% methanol for 30 minutes, and finally rinsed 3 times with deionized water. The crystal violet stain was eluted with 0.1 M sodium citrate (pH 4.2) in 50% ethanol and the number of adherent cells in each well was evaluated by the measurement of absorbance at 596 nm using a microplate reader (BioRad). Cells were also photographed using a fluorescence microscope (Carl Zeiss).

Cell migration assays
Migration of HUVECs was assessed using modified Boyden chambers (Costar) with the upper chamber containing a polycarbonate membrane filter of 8.0 μm pore size. Membrane surfaces were coated with vitronectin (5 μg/ml) for 1 hour at 37°C. Both transfected and non-transfected HUVECs at early passages (4-8) were starved in 0.5% FBS-containing αMEM for 4 hours, and then harvested with trypsin/EDTA. After suspension in the medium for 20 minutes and transfer to the migration buffer (αMEM containing 0.1% BSA), cells were seeded at a density of 5×10^4 cells per well (final volume, 100 μl) on the filter. Cell migration was induced by addition of 600 μl migration buffer containing 20 ng/ml VEGF to the lower chamber. After incubation for 4 hours at 37°C, the number of migrating cells was counted under a microscope using a hemocytometer (6 fields per filter) after staining of the cells on the lower surface of the membrane filter with Hematoxylin. Cells on the upper surface of the membrane were removed by mechanical cleaning and extensive washing with deionized water.

In vivo tumor growth model
Anti-tumorigenic and angiogenic activities were evaluated by in vivo tumor growth model of the melanoma cell line BL-6 that forms vascular-rich solid tumors when implanted subcutaneously. Tumors were generated by subcutaneously implanting 1×10^6 BL-6 melanoma cells transfected with either Ad-shChM-I, Ad-shTeM or Ad-EGFP onto the backs of 6- to 8-week-old C57BL/6 mice. Animals were humanely sacrificed at the specific indicated times according to institutional animal care guidelines and tumor weights were measured. Three independent experiments with 16 mice in each group (shChM-I- or shTeM-transfected cells, mock transfected cells, and wild-type cells) were carried out. Animals were sacrificed on day 21 for immunohistological analysis. Data are given as the mean±s.d. (standard deviation) of four mice from each group. For the measurement of vascular density in tumors, micro cryostat sections of each tumor were prepared according to standard procedures. The sections were incubated with 1% BSA in PBS for 4 hours at room temperature, followed by incubation with a monoclonal antibody against PECAM (CD31: Molecular Probes) at a dilution of 1:400 in 1% BSA in PBS overnight. After further incubation with rhodamine-conjugated antibody and 10 nM Hoechst dye 33342 (Sigma-Aldrich) for 2 hours, the sections were photographed and the images merged with a fluorescence microscope coupled to an imaging computer system (Carl Zeiss, Oberkochen, Germany).

Statistical analysis
Statistical analyses for comparison of data were made with one-way analysis of variance (ANOVA), followed by Scheffé’s multicomparison test. A P value of <0.05 was considered statistically significant.

Results
Immunodetection of endogenous TeM protein in mice
A Kyte-Doolittle hydropathy plot revealed that TeM is a type II transmembrane protein with a C-terminal 63 amino acid region (from Phe^{255} to Val^{317}) that shows high homology to a C-terminal domain of mature ChM-I (Fig. 1) (Shukunami et al., 2001). TeM has a hydrophobic transmembrane region in its N terminus, but a classic signal sequence was not found. Additionally, a cleavage site (Arg-Glu-Arg-Arg) present in ChM-I is not present in TeM (Shukunami et al., 2001), although another potential cleavage motif (Arg-X-X-Arg) is present at position 233-236 in both human and mouse TeM (Barr, 1991). To further analyze the biochemical characteristics of TeM proteins, COS7 cells were transiently transfected with cDNAs containing the entire coding region of TeM that had been separately FLAG-tagged at both the N and C terminus.

Fig. 1. Structural features of human tenomodulin (TeM) and the human chondromodulin-I (ChM-I) precursor proteins deduced from their cDNA sequences. Analysis of primary amino acid sequences reveals several structural features in the putative TeM protein. These include a type II transmembrane domain at the N terminus, a BRICHOS domain and a cysteine-rich domain (Sanchez-Pulido et al., 2002). The TeM protein contains two N-glycosylation sites within the BRICHOS domain. The highest homology with the ChM-I precursor was scored in the cysteine-rich domain at the C terminus (Sachdev et al., 2001; Shukunami et al., 2001).
As predicted from the deduced amino acid sequence, expressed recombinant TeM protein was detected by western blotting as a double band, with approximate molecular masses of 40 and 45 kDa, that most probably resulted from differential glycosylation (Yamana et al., 2001).

No immunoreactive band was detected in culture medium from COS7 cells that had been transfected with cDNA containing full-length human TeM (Fig. 2A). However, upon transfection of either the FLAG-tagged C-terminal 116 amino acids (Glu<sup>202</sup>-Val<sup>317</sup>) of TeM or the FLAG-tagged C-terminal 120 amino acids (Glu<sup>215</sup>-Val<sup>334</sup>) of the ChM-I precursor, under the control of the preprotrypsin secretion signal, both FLAG-shTeM or FLAG-shChM-I bands could indeed be detected in the culture media as well as in cell lysates (Fig. 2A). Cell-surface biotinylation experiments indicated that TeM is present as a transmembrane protein with its C terminus exposed to the exterior surface of cells (Fig. 2B). The expression of full-length C-terminal FLAG-tagged hTeM on the cell surface of transfected COS7 cells was also demonstrated using confocal fluorescence microscopy, which detected the specific interaction of FITC-conjugated anti-FLAG M2 monoclonal antibodies with the FLAG epitope (Fig. 2C). Permeabilized cells transfected with hTeM, FLAG-tagged at either terminus showed diffuse fluorescent signals throughout the cell bodies (Fig. 2D,F). No fluorescent labeling was observed in COS7 cells transfected with empty vector (Fig. 2G,H). These studies indicated that TeM is a type II transmembrane protein with a short cytoplasmic tail and with the C terminus expressed on the exterior cell surface.

We performed a series of biochemical analyses of the translation products of the TeM gene, using a COS7 cell experimental system, as the biochemistry of endogenous TeM proteins that have not been previously reported. Extracts from mouse muscle and liver were analyzed by SDS-PAGE and we...
observed electrophoresis patterns of these extracts that were similar to previously reported observations (Louis and Sekeris, 1976; Scopes and Penny, 1971). We then performed western blot analysis using an antibody raised against synthetic peptides corresponding to the human TeM sequence from Thr124 to Glu136 (Fig. 3). Endogenous mouse TeM was indicated by the presence of a double band with a molecular mass of approximately 45 kDa in extracts from muscle. By contrast, no immunoreactive band was detected in extracts from liver (Fig. 3). We also performed western blot analysis using antibodies raised against the human TeM sequence Ile245 to Gly252 (Yamana et al., 2001) and obtained similar results (data not shown). Thus, there was no indication of the existence of shorter cleaved forms of TeM in muscle. As revealed by immunohistochemistry, TeM proteins was exclusively present in epimysium and tendon, where TeM transcripts were abundantly expressed (data not shown) (Shunukami et al., 2001). These results indicate that TeM is a type II transmembrane protein and that its C terminus is exposed on the exterior surface of both epimysium and tendon/ligaments during embryonic development.

Inhibition of tube formation of HUVECs following treatment with conditioned medium from hTeM transfected COS7 cells

To test for possible biological activity of TeM proteins in vascular endothelial cells, we prepared conditioned medium from COS7 cells that had been transfected with either the full-length or the secretable C-terminal 116 amino acids of human TeM. For comparison, the C-terminal mature protein derived from the ChM-I precursor was also expressed in COS7 cells and the conditioned medium was collected after 48 hours. Production of shChM-I or shTeM was confirmed by western blotting (Fig. 2A). When treated with conditioned medium containing either shTeM (the secreted C-terminal domain of TeM) or shChM-I (the secreted mature ChM-I domain), HUVECs failed to form tubular structures in culture on Matrigel (Fig. 4A,B). Conditioned medium from COS7 cells transfected with the entire extracellular domain of TeM, from His52 to Val317, also inhibited tube formation of HUVECs (data not shown). By contrast, conditioned medium prepared from mock-transfected COS7 cells did not affect HUVEC tube formation (Fig. 4A,B). In addition, conditioned medium from COS7 cells expressing other regions of TeM (His52-Glu201 or His52 to Glu254) also did not inhibit tube formation of HUVECs (data not shown).

Recombinant adenoviral expression of the human TeM C-terminal 116-amino acids and the human ChM-I C-terminal 120-amino acids

To examine the angiogenic properties of TeM, we generated adenoviral vectors that expressed either the C-terminal region of human TeM, containing residues Glu202 to Val317 (Ad-shTeM), or full-length human TeM (Ad-hTeM) (Fig. 5A). For comparison, we similarly constructed an adenoviral vector (Ad-shChM-I) expressing the 120 amino acids corresponding to mature human ChM-I (Fig. 5A). The adenoviral vectors had been modified to express GFP fusion protein products under the control of an IRES cassette and containing the preprotrepsin secretion signal. For the efficient generation of recombinant adenoviruses, we utilized the Cre-loxP recombination system and the circular form of the adenoviral genome cloned into a cosmid for the purposes of constructing E1-substituted adenoviral vectors (Tashiro et al., 1999). In this system, the backbone of the pALC3.0 cosmid vector was modified by replacing the E1 region of the circular form of adenoviral genome with the loxP-flanked cosmid cassette.

Cotransfection of a Cre-expression plasmid with the indicated pALC3.0 cosmid vector into 293 cells efficiently generates recombinant adenoviral vector that contains the indicated expression cassette, but lacks the cosmid vector backbone. Within 8 days of transfection, cytopathic effects (CPE) was visible in each of the wells containing 293 cells that had been cotransfected with the cosmid vector containing the expression cassette and the Cre-expression plasmid. Most HUVECs was deemed to have been infected as determined by the expression of EGFP (Fig. 5B). As shown in Fig. 5C, normal Dil-AcLDL up-take was observed in HUVECs transduced with Ad-EGFP.

Secretion of shTeM or shChM-I into the conditioned medium of HUVECs following adenoviral transduction was confirmed by western blotting with anti-N-terminal FLAG monoclonal antibodies. As shown in Fig. 5D, HUVECs infected with Ad-shTeM synthesized and secreted a ~21 kDa protein which is the predicted molecular mass. Additionally, HUVECs infected with Ad-shChM-I produced a ~25 kDa protein, which was visible as a broad band, probably the result of glycosylation at Asn243 (Fig. 5D). No immunoreactive bands were detected in conditioned medium from HUVECs transduced with control adenoviral vectors lacking an expression cassette or from uninfected HUVECs.

Inhibition of VEGF-mediated HUVEC tube formation by expression of either shTeM (Glu202-Val317) or shChM-I (Glu215-Val334)

HUVECs assemble into multicellular capillary-like structures
Anti-angiogenic properties of TeM when plated on Matrigel in the presence of 10 ng/ml VEGF, uninfected HUVECs (wild-type) or HUVECs infected with control adenovirus expressing only EGFP (Ad-EGFP) elongated and assembled themselves into multicellular capillary-like structures within a few hours (Fig. 6A). By contrast, tube formation was significantly inhibited in HUVECs transduced with Ad-shChM-I (Fig. 6A). Similarly there was a significant impairment of the cellular response of capillary formation to VEGF, when HUVECs were infected with Ad-shTeM (Fig. 6A). The total lengths of the capillary-like structures was significantly shorter in adenoviral-transduced HUVECs than in either wild-type cells or Ad-EGFP transfectants (Fig. 6B). We also established stable transfectants from the mouse endothelial cell line MSS31 (Namba et al., 2000) to measure the effects of forced expression of either shTeM or shChM-I under the control of the chicken β-actin promoter, and confirmed that FGF-2-induced tube formation of these cells on Matrigel was also markedly inhibited (data not shown). HUVECs were also transduced with Ad-hTeM to express full-length membrane-tethered TeM and although it cannot be readily evaluated as to what extent insoluble membrane tethered TeM affects junctional contacts between endothelial cells, apparent tube-like cellular alignments were visible (Fig. 6A,B).

Effects of adenoviral expression of both shTeM and hChM-I on cellular proliferation, migration and attachment of HUVECs

The rate of DNA synthesis in HUVECs after infection with adenovirus was determined by measuring BrdU incorporation. Quiescent cultures were incubated with or without VEGF (20 ng/ml) for 12 hours, and the cells were labeled with BrdU during the last 4 hours of incubation. VEGF markedly stimulated DNA synthesis in non-transfected wild-type HUVECs (Fig. 7). As the mitogenic function of VEGF requires the activation of p42/44 MAP kinase (Hata et al., 1999; Seetharam et al., 1995), the MAP kinase inhibitor PD98059 completely abolished the stimulation of DNA synthesis, in response to VEGF, in both uninfected and adenoviral transduced cells. Moreover, control vector, Ad-EGFP, did not in any way inhibit VEGF stimulation of DNA synthesis (Fig. 7). Hence, adenoviral infection per se does not affect either the basal or the stimulated rate of DNA metabolism in these cells. However, adenoviral expression of shTeM and shChM-I in HUVECs resulted in a 40-50% reduction in VEGF-stimulated DNA synthesis (Fig. 7).

To examine the impact of shTeM and shChM-I on endothelial cell migration, HUVECs were infected with Ad-shTeM or Ad-shChM-I (Fig. 8). Migration was evaluated using a modified Boyden chamber assay with vitronectin-coated filters. As a chemoattractant, VEGF (20 ng/ml) was added to the lower chamber. HUVECs infected with or without recombinant adenoviruses were cultured in αMEM containing 0.5% FBS for 4 hours and then harvested with trypsin/EDTA. After suspending cells in the culture medium for 20 minutes and washing in migration buffer (αMEM containing 0.1% BSA), cells were seeded at a density of 5×10^4 cells per well (final volume, 100 μl) on the upper surface of filters. After 4 hours of incubation, VEGF clearly induced migration of both
uninfected and Ad-EGFP-transduced control HUVECs through a porous filter coated with vitronectin (Fig. 8A). By contrast, the number of migrating cells was markedly reduced when they were transduced with either shTeM or shChM-I (Fig. 8B).

We then evaluated whether either shTeM or shChM-I altered cellular attachment to different extracellular matrices. HUVECs infected with or without adenoviruses were seeded onto plastic dishes coated with extracellular matrix components such as type I collagen, fibronectin and vitronectin. Following 1 hour of incubation at 37°C, unattached cells were removed by a gentle rinse with PBS and plates were evaluated for adhesion and spreading (Fig. 9A). Both uninfected and Ad-EGFP-transduced control cultures had similar numbers of attached cells and showed a polygonal extension on dishes coated with each of the extracellular matrix proteins (Fig. 9B). However, cells expressing shTeM or shChM-I appeared rounded and failed to spread on vitronectin-coated dishes.

Suppression of both angiogenesis and tumor growth
Both the growth and persistence of solid tumors are dependent on angiogenesis, the inhibition of which has been shown to be an effective strategy for tumor treatment. To test the antiangiogenic and anti-tumor activities of shTeM or shChM-I in
vivo, BL-6 melanoma cells were transduced with Ad-shTeM, Ad-shChM-I or Ad-EGFP (control) and 1×10⁶ of each set of transduced cells were subcutaneously injected into C57BL/6 mice. Both wild-type melanoma cells and Ad-EGFP-transduced melanoma cells formed tumors rapidly. By contrast, however, Ad-shTeM- and Ad-shChM-I-transduced melanoma cells formed tumors that were 46% and 60% smaller, respectively, when compared to Ad-EGFP-transduced melanoma cells (Fig. 10A-C).

Angiogenesis within these melanoma cell tumor tissues was evaluated by counting the number of microvessels in sections stained with antibodies reactive to PECAM-1, a marker for vascular endothelial cells. As shown in Fig. 10D, adenoviral expression of shTeM or shChM-I resulted in visible inhibition of angiogenesis in implanted tumors and microvessel densities were 63±7% and 71±5% of Ad-EGFP transduced tumor, respectively (Fig. 10E). By contrast to the inhibitory effect of shTeM or shChM-I on the proliferation of HUVECs (Fig. 7), the growth rate of BL-6 melanoma cells was not affected upon transduction of Ad-shTeM or Ad-shChM-I (data not shown). These data therefore indicate that adenovirus-mediated overexpression of shTeM or shChM-I inhibited tumor growth by counteracting tumor-induced angiogenesis.

Discussion

TeM protein shows the highest sequence homology to the ChM-I precursor in its C-terminal cysteine-rich domain (Fig. 1) (Brandau et al., 2001; Shukunami et al., 2001; Yamana et al., 2001). In the case of the ChM-I precursor, this domain contains all eight cysteine residues found in the mature ChM-I protein, which form four disulfide bonds with a specific configuration. These disulfide bonds appear to be critical for the anti-angiogenic activity of ChM-I in vitro (Hiraki et al., 1997; Hiraki et al., 1999). However, owing to its hydrophobic nature and the restricted configuration of these disulfide bonds,
resulted in the inhibition of angiogenic responses in HUVECs. We demonstrate in this study that the forced expression of the C-terminal portion of the precursor protein. angiogenic properties of ChM-I were evident upon forced tube formation and cell migration (Figs 6-8). Thus, the anti-

It has, so far, not been possible to synthesize the ChM-I cysteine-rich domain alone. We therefore decided to carry out experiments utilizing the forced expression and secretion of the C-terminal 116 amino acids of human TeM (shTeM) tagged with a FLAG epitope in HUVECs under the control of the preprotrypsin secretion signal and the CAG promoter (Fig. 5). For comparison, the C-terminal 120 amino acids of the human ChM-I precursor (shChM-I, corresponding to mature ChM-I protein) were similarly expressed using adenovirus vectors.

As predicted, based upon previous observations (Hiraki et al., 1997; Hiraki et al., 1999), autocrine secretion of shChM-I resulted in the marked inhibition of angiogenic responses in HUVECs induced by VEGF, which included DNA synthesis, cell proliferation and cell adhesion to either type I collagen or fibronectin (data not shown). Cell attachment was similarly modulated by the expression and secretion of shTeM or shChM-I (Fig. 9). Adhesion of HUVECs to vitronectin-coated dishes was significantly reduced, whereas adhesion to either type I collagen or fibronectin was not affected in these transduced cells (data not shown). Cell migration was similarly modulated by the expression and secretion of shTeM or shChM-I (Fig. 9). Adhesion of HUVECs to vitronectin-coated dishes was significantly reduced, whereas adhesion to either type I collagen or fibronectin was not affected in these transduced cells (data not shown).

In solid tumors, the normal configuration of blood vessels is generally disrupted and the microvessels are primitive and leaky. It also seems to be relatively easier to counteract tumor-induced angiogenesis by administration of a single anti-angiogenic factor, in comparison to the modification of vascular networks during development in which angiogenesis is more precisely controlled by multiple mechanisms. Indeed, clinical and laboratory studies have already reported robust evidence indicating that tumor angiogenesis is inhibited by administration of anti-angiogenic factors (Tonini et al., 2003).

We have also reported that recombinant ChM-I protein effectively suppresses the growth of chondrosarcoma and colon adenocarcinoma by inhibiting angiogenesis in vivo (Hayami et
Anti-angiogenic properties of TeM (al., 1999). It is likely, therefore, that the C-terminal ChM-I-like domain of TeM has anti-tumor activity in vivo, and indeed expression of both Ad-shTeM and Ad-shChM-I results in the effective inhibition of angiogenesis, followed by suppression of tumor growth (Fig. 10A-C). The number of vascular vessels was also decreased in tumors transduced with either Ad-shTeM or Ad-shChM-I (Fig. 10D-E). These results strongly suggest that shTeM acts as an angiogenesis inhibitor both in vitro and in vivo. As already demonstrated by several other groups, anti-angiogenic gene therapy, with adenoviral vectors expressing anti-angiogenic proteins, could prove to be effective future treatments for solid tumors. The conserved anti-angiogenic domain present in both TeM and ChM-I might therefore be a useful target for an anti-tumor drug.

Many angiogenesis inhibitors identified to date are proteolytic fragments of larger precursor molecules (Tonini et al., 2003). Mature human ChM-I (120 amino acids) is also secreted from chondrocytes as a C-terminal fragment of a type II transmembrane protein (334 amino acids) after cleavage at its furin processing site (Arg-Glu-Arg-Arg) (Hiraki et al., 1997). No processing occurs when this precursor cleavage site is mutated to RERQ-SLVR or when the precursor cDNA is expressed in the furin-deficient CHO cell line (Azizan et al., 2001). Similarly, TeM is a putative type II transmembrane protein containing a BRICHOS domain, the functional role of which has not been fully elucidated (Sanchez-Pulido et al., 2002). However, unlike the ChM-I precursor, the TeM protein does not contain a furin cleavage site (Arg-Glu-Arg-Arg) (Fig. 1), although there is another potential processing site, Arg-Xxx-Xxx-Arg (Barr, 1991; Shukunami et al., 2001; Yamana et al., 2001). Cell surface biotinylation and cell surface labeling experiments indicate that the TeM protein is indeed expressed as a transmembrane protein in a type II configuration.

In conventional angiogenesis assays, expression of full-length hTeM did not inhibit tube formation in HUVECs (Fig. 6). A novel member of the TNF family VEGI is a type II transmembrane protein predominantly expressed in endothelial cells (Zhai et al., 1999). The anti-angiogenic properties of VEGI were also demonstrated following forced expression of its secreted form via gene transfer, but no anti-angiogenic activity was evident when full length VEGI was expressed. Intracellular signaling pathways, mediating the actions of membrane-tethered ligands, have been described in some instances such as the Notch-Delta or the Ephrin-Eph system (Sullivan and Bicknell, 2003). However, the molecular mechanism by which the C-terminal region of TeM or ChM-I exerts its anti-angiogenic effects has not yet been described. As previously reported (Shukunami et al., 2001), endogenous TeM is specifically expressed in mouse embryos on tenocytes and ligament fibroblasts that give rise to...
hypovascular dense connective tissues during development. When considering the anti-angiogenic potentials of the TeM C-terminal region, therefore, it is reasonable to assume that membrane-tethered TeM protein participates in forming an anti-angiogenic surface on cells of the dense connective tissue. It is possible to speculate also that TeM takes part in the regulation of either angiogenesis or vascular invasion through anti-angiogenic cell surface contacts with adjacent endothelial cells in dense connective tissues, under both normal and pathological conditions. However, because of the current lack of an appropriate assay system, it is still uncertain whether membrane-tethered TeM acts as an angiogenesis inhibitor on such cell surfaces.

Accumulating evidence suggests that the extracellular domains of several integral type I or type II transmembrane proteins are cleaved and released from cells in a soluble form by ectodomain shedding (Kheradmand and Werb, 2002). Ectodomain shedding has been reported to profoundly affect the biological activity of its target proteins and to play a critical role during development as demonstrated in TACE/ADAM-17 knockout mice which have abnormal lung development and die at birth (Zhao et al., 2001). Several members of the ADAM family and of the metalloproteinases are involved in the release of transmembrane proteins (Black and White, 1998). As demonstrated in this report, endogenous TeM protein was detected by western blotting as a double band of between ~40 and ~45 kDa in tissue extracts (Fig. 2C). No immunoreactivity with bands of smaller molecular mass was detected, indicating the absence of TeM cleavage products. Immunohistochemical analyses of TeM were consistent with in situ hybridization data showing expression of TeM mRNA in the epimysium of skeletal muscle and tendinous dense connective tissue.
surrounding the bone precursors (data not shown). Although cleavage products of TeM were not detected in extracts of skeletal muscle from 4-week-old mice by western blot analysis, this does not preclude the possibility that the extracellular domain of TeM might be cleaved by shedding enzymes and released from the cells as a soluble factor to modify angiogenesis during development. Indeed, we found that ChM-I could in fact act as a substrate for MMP-13, which is expressed in hypertrophic chondrocytes (unpublished data).

Thus, it is also possible to speculate that some metalloproteinases or ADAMs expressed in developing tendons and ligaments may participate in the processing of the extracellular domain of TeM.

The locomotive organs contains a variety of specialized forms of supporting connective tissues. Among them, cartilage and tendon/ligaments are avascular or hypovascular as characterized by a poor and limited blood supply (Benjamin and Ralphs, 2000; KueKutter and Pauli, 1983; Young and Heath, 2000). By contrast, the adjacent mesenchyme including muscle, bone and synovium are well vascularized. Microcapillaries in these tissues never invade cartilage or tendon/ligaments under physiological conditions and the anti-angiogenic properties of these tissues are regulated by multiple molecular mechanisms. TeM proteins are localized to the sites of attachment of muscle to skeletal tissues that delimit the extension of the vascularisation (C.S., unpublished data). Both the bioactivity and localization of ChM-I and TeM indicate that these molecules may play a part in the maintenance of an anti-angiogenic state.

We would like to thank Dr Ken-ichi Iyama (Kumamoto University) for his helpful suggestions. Thanks are also due to Miss Y. Kubo for her valuable secretarial help. This work was partly supported by grants from the Research Fund for the Future Program from the Japan Society for the Promotion of Science (to Y.H. and to C.S.), and Grants-in-Aid (to Y.H. and to C.S.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References
Azizan, A., Holaday, N. and Neame, P. J. (2001). Post-translational processing of bovine chondromodulin-I. J. Biol. Chem. 276, 23632-23638.
Barr, P. J. (1991). Mammalian subtilisins: the long-sought dibasic processing endopeptidase. Cell 66, 1-3.
Benjamin, M. and Ralphs, J. R. (2000). The cell and developmental biology of tendons and ligaments. Int. Rev. Cytol. 196, 85-130.
Black, R. A. and White, J. M. (1998). ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 10, 654-659.
Brandau, O., Meindl, A., Fassler, R. and Aszodi, A. (2001). A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I. Dev. Dyn. 221, 72-80.
Brooks, P. C., Clark, R. A. and Cheres, D. A. (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571.
Cao, Y., Chen, A., An, S. S., Ji, R. W., Davidson, D. and Llinas, M. (1997). Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 272, 22924-22928.
Carmeliet, P., Ferreira, V., Breier, G., Pollevey, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vanhendehoek, A., Harpal, K., Eberhardt, C. et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
Eliceiri, B. P. and Cheres, D. A. (1999). The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103, 1227-1230.
Folkman, J. and Haedenschild, C. (1980). Angiogenesis in vitro. Nature 288, 551-556.
Grant, D. S., Lelkes, P. I., Fukuda, K. and Kleinman, H. K. (1991). Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro. In Vitro Cell. Dev. Biol. 27A, 327-336.
Hata, Y., Rook, S. L. and Aiello, L. P. (1999). Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 48, 1145-1155.
Hayami, T., Shukunami, C., Mitsu, K., Endo, N., Tokunaga, K., Kondo, J., Takahashi, H. E. and Hiraki, Y. (1999). Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEMS Lett. 458, 436-440.
Hiraki, Y., Inoue, H., Iyama, K., Kamizono, A., Ochiai, M., Shukunami, C., Iijima, S., Suzuki, F. and Kondo, J. (1997). Identification of chondromodulin-I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epithelial cartilage. J. Biol. Chem. 272, 32419-32426.
Hiraki, Y., Mitsui, K., Endo, N., Takahashi, K., Hayami, T., Inoue, H., Shukunami, C., Tokunaga, K., Kono, T., Yamada, M. et al. (1999). Molecular cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, and its expression in Chinese hamster ovary cells. Eur. J. Biochem. 260, 869-878.
Kheradmand, F. and Werb, Z. (2002). Shedding light on sheddases: role in growth and development. BioEssays 24, 8-12.
KueKutter, K. E. and Pauli, B. U. (1983). Vascularity of cartilage. In Cartilage, vol. 1 (ed. B. K. Hall), pp. 281-312. New York: Academic Press.
Louis, C. and Sekeris, C. E. (1976). Isolation of informosomes from rat liver. Effects of alpha-aminatin and actinomycin D. Exp. Cell Res. 102, 317-328.
Mori, Y., Hiraki, Y., Shukunami, C., Kakudo, S., Shiokawa, M., Kagoshima, M., Mano, H., Hakeda, Y., Kurokawa, T., Suzuki, F. et al. (1997). Stimulation of osteoblast proliferation by the cartilage-derived growth promoting factors chondromodulin-I and -II. FEMS Lett. 406, 310-314.
Nakamichi, Y., Shukunami, C., Yamada, T., Aihara, K., Kawano, H., Sato, T., Nishizaki, Y., Yamamoto, Y., Shindo, M., Yoshimura, K. et al. (2003). Chondromodulin-I is a bone remodeling factor. Mol. Cell. Biol. 23, 636-644.
Nakamura, T., Aoki, S., Kitajima, K., Takahashi, T. and Matsumoto, K. (2001). Molecular cloning and characterization of Kremen, a novel kringle-containing transmembrane protein. Biochim. Biophys. Acta 1518, 63-72.
Nakayama, J., Tsuchida, T., ToyoFuku, K., Shimokawa-Kuroki, R., Taniguchi, S. and Hori, Y. (1994). Different sensitivities of the murine melanomas Bl-6 and Bl-6-beta m to local injections of interleukin-2 (IL-2). Analysis of gangliosides after the treatment. Melanoma Res. 4, 297-302.
Namba, K., Abe, M., Saito, S., Satake, M., Ohmoto, T., Watanabe, T. and Sato, Y. (2000). Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MS531. Oncogene 19, 106-114.
Neame, P. J., Treep, J. T. and Young, C. N. (1990). An 18-kDa glycoprotein from bovine nasal cartilage. Isolation and primary structure of small, cartilage-derived glycoprotein. J. Biol. Chem. 265, 9628-9633.
Niwa, H., Yamamura, K. and Miyazaki, J. (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199.
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J. (1999). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
Sachdev, S. W., Dietz, U. H., Oshima, Y., Lang, M. R., Knapik, E. W., Hiraki, Y. and Shukunami, C. (2001). Sequence analysis of zebrafish chondromodulin-I and expression profile in the notochord and chordogenic regions during cartilage morphotogenesis. Mech. Dev. 105, 157-162.
Sanchez-Pulido, L., Devos, D. and Valencia, A. (2002). BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem. Sci. 27, 329-332.
Scopes, R. K. and Penny, I. F. (1971). Subunit sizes of muscle proteins, as
determined by sodium dodecyl sulphate gel electrophoresis. *Biochim. Biophys. Acta* **236**, 409-415.

Seetharam, L., Gotoh, N., Maru, Y., Neufeld, G., Yamaguchi, S. and Shibuya, M. (1995). A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. *Oncogene* **10**, 135-147.

Shukunami, C., Iyama, K., Inoue, H. and Hiraki, Y. (1999). Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. *Int. J. Dev. Biol.* **43**, 39-49.

Shukunami, C., Oshima, Y. and Hiraki, Y. (2001). Molecular cloning of tenomodulin, a novel chondromodulin-I related gene. *Biochem. Biophys. Res. Commun.* **280**, 1323-1327.

Sullivan, D. C. and Bicknell, R. (2003). New molecular pathways in angiogenesis. *Br. J. Cancer* **89**, 228-231.

Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N. and Yancopoulos, G. D. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* **87**, 1171-1180.

Tang, S., Gao, Y. and Ware, J. A. (1999). Enhancement of endothelial cell migration and in vitro tube formation by TAP20, a novel beta 5 integrin-modulating, PKC theta-dependent protein. *J. Cell Biol.* **147**, 1073-1084.

Tarui, T., Miles, L. A. and Takada, Y. (2001). Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. *J. Biol. Chem.* **276**, 39562-39568.

Tashiro, F., Niwa, H. and Miyazaki, J. (1999). Constructing adenoviral vectors by using the circular form of the adenoviral genome cloned in a cosmid and the Cre-loxP recombination system. *Hum. Gene Ther.* **10**, 1845-1852.

Tonini, T., Rossi, F. and Claudio, P. P. (2003). Molecular basis of angiogenesis and cancer. *Oncogene* **22**, 6549-6556.

Yamana, K., Wada, H., Takahashi, Y., Sato, H., Kasahara, Y. and Kiyoki, M. (2001). Molecular cloning and characterization of CHM1L, a novel membrane molecule similar to chondromodulin-I. *Biochem. Biophys. Res. Commun.* **280**, 1101-1106.

Young, B. and Heath, J. (2000). Connective tissues. In *Wheater’s Functional Histology* (eds H. Burkitt, B. Young and J. Heath), pp. 97-192. Edinburgh, UK: Churchill Livingstone.

Zhai, Y., Ni, J., Jiang, G. W., Lu, J., Xing, L., Lincoln, C., Carter, K. C., Janat, F., Kozak, D., Xu, S. et al. (1999). VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. *FASEB J.* **13**, 181-189.

Zhao, J., Chen, H., Peschon, J. J., Shi, W., Zhang, Y., Frank, S. J. and Warburton, D. (2001). Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. *Dev. Biol.* **232**, 204-218.